Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer

Sandro Pignata, Rossella Lauria, Francesco Perrone, Ettore Ferrari, Edoardo Biondi, Antonio Maffeo, Alessandro Morabito, Raffaele Graziano, Chiara Carlomagno, Giuseppe De Placido, Giro Gallo, Angelo Raffaele Bianco, Mario Pergola, Sabino De Placido

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Cisplatin and carboplatin are both active in ovarian cancer with different toxicity profiles; thus, dose intensification may be possible by combining them. The aim of the present study was to determine the maximum tolerated dose of carboplatin combined with fixed doses of cisplatin and cyclophosphamide without and with support of lenograstim. Cisplatin (60 mg/m2), cyclophosphamide (600 mg/m2) and carboplatin (starting dose 200 mg/m2) were given on day 1 every 3 weeks for 4 cycles. Escalated dose levels for carboplatin were planned by increments of 50 mg/m2 per level. Lenograstim (L) (150 μg/m2/day subcutaneously) was given in case of grade 4 leukopenia (levels without support) or from day 5 up to leukocyte >10,000/mm3 after nadir (levels with support). Four levels were studied (200, 250, 250 + lenograstim, 300 + lenograstim) with 7, 7, 8, and 7 patients enrolled, respectively. Unacceptable toxicity was induced in 1 patient at the level 1 (grade 4 thrombocytopenia), in 4 patients at the level 2 (2 prolonged grade 2 leukopenia, 1 grade 4 leukopenia with concomitant grade 4 thrombocytopenia and I grade 4 thrombocytopenia), in 1 patient at the level 2 + L (grade 4 thrombocytopenia) and in 3 patients at the level 3 + L (3 grade 4 thrombocytopenia). Thus, 200 mg/m2 and 250 mg/m2 were defined as carboplatin MTDs without and with lenograstim support, respectively. Median total platinum (cisplatin + 1/4 carboplatin) delivered dose-intensities were 33, 32, 38 and 44 mg/m2/week at the four levels, respectively. Hematological toxicity was overall mild. In no case was febrile neutropenia recorded. Grade 4 thrombocytopenia was always transient and never symptomatic. Grade 3 vomiting was the only severe non-hematological toxicity reported in 5 patients. Out of 16 patients with measurable disease, 11 objective responses were obtained (5 complete and 6 partial) for an overall response rate of 69% (95% exact CL 41-89%). Recommended dose of carboplatin is 200 mg/m2 without and 250 mg/m2 with support of lenograstim when combined with cisplatin 60 mg/m2 and cyclophosphamide 600 mg/m2. Dose limiting toxicity is persistent leukopenia without and grade 4 thrombocytopenia with support of lenograstim.

Original languageEnglish
Pages (from-to)175-180
Number of pages6
JournalInternational Journal of Oncology
Volume11
Issue number1
Publication statusPublished - 1997

Fingerprint

Carboplatin
Ovarian Neoplasms
Cyclophosphamide
Cisplatin
Leukopenia
Therapeutics
Febrile Neutropenia
Maximum Tolerated Dose
lenograstim
Platinum
Vomiting
Leukocytes
Thrombocytopenia 4

Keywords

  • Carboplatin
  • Cisplatin
  • Ovarian neoplasms
  • Platinum dose-intensity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer. / Pignata, Sandro; Lauria, Rossella; Perrone, Francesco; Ferrari, Ettore; Biondi, Edoardo; Maffeo, Antonio; Morabito, Alessandro; Graziano, Raffaele; Carlomagno, Chiara; De Placido, Giuseppe; Gallo, Giro; Bianco, Angelo Raffaele; Pergola, Mario; De Placido, Sabino.

In: International Journal of Oncology, Vol. 11, No. 1, 1997, p. 175-180.

Research output: Contribution to journalArticle

Pignata, S, Lauria, R, Perrone, F, Ferrari, E, Biondi, E, Maffeo, A, Morabito, A, Graziano, R, Carlomagno, C, De Placido, G, Gallo, G, Bianco, AR, Pergola, M & De Placido, S 1997, 'Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer', International Journal of Oncology, vol. 11, no. 1, pp. 175-180.
Pignata, Sandro ; Lauria, Rossella ; Perrone, Francesco ; Ferrari, Ettore ; Biondi, Edoardo ; Maffeo, Antonio ; Morabito, Alessandro ; Graziano, Raffaele ; Carlomagno, Chiara ; De Placido, Giuseppe ; Gallo, Giro ; Bianco, Angelo Raffaele ; Pergola, Mario ; De Placido, Sabino. / Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer. In: International Journal of Oncology. 1997 ; Vol. 11, No. 1. pp. 175-180.
@article{58e68abdd0a74d34b9a0a49cafab27ef,
title = "Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer",
abstract = "Cisplatin and carboplatin are both active in ovarian cancer with different toxicity profiles; thus, dose intensification may be possible by combining them. The aim of the present study was to determine the maximum tolerated dose of carboplatin combined with fixed doses of cisplatin and cyclophosphamide without and with support of lenograstim. Cisplatin (60 mg/m2), cyclophosphamide (600 mg/m2) and carboplatin (starting dose 200 mg/m2) were given on day 1 every 3 weeks for 4 cycles. Escalated dose levels for carboplatin were planned by increments of 50 mg/m2 per level. Lenograstim (L) (150 μg/m2/day subcutaneously) was given in case of grade 4 leukopenia (levels without support) or from day 5 up to leukocyte >10,000/mm3 after nadir (levels with support). Four levels were studied (200, 250, 250 + lenograstim, 300 + lenograstim) with 7, 7, 8, and 7 patients enrolled, respectively. Unacceptable toxicity was induced in 1 patient at the level 1 (grade 4 thrombocytopenia), in 4 patients at the level 2 (2 prolonged grade 2 leukopenia, 1 grade 4 leukopenia with concomitant grade 4 thrombocytopenia and I grade 4 thrombocytopenia), in 1 patient at the level 2 + L (grade 4 thrombocytopenia) and in 3 patients at the level 3 + L (3 grade 4 thrombocytopenia). Thus, 200 mg/m2 and 250 mg/m2 were defined as carboplatin MTDs without and with lenograstim support, respectively. Median total platinum (cisplatin + 1/4 carboplatin) delivered dose-intensities were 33, 32, 38 and 44 mg/m2/week at the four levels, respectively. Hematological toxicity was overall mild. In no case was febrile neutropenia recorded. Grade 4 thrombocytopenia was always transient and never symptomatic. Grade 3 vomiting was the only severe non-hematological toxicity reported in 5 patients. Out of 16 patients with measurable disease, 11 objective responses were obtained (5 complete and 6 partial) for an overall response rate of 69{\%} (95{\%} exact CL 41-89{\%}). Recommended dose of carboplatin is 200 mg/m2 without and 250 mg/m2 with support of lenograstim when combined with cisplatin 60 mg/m2 and cyclophosphamide 600 mg/m2. Dose limiting toxicity is persistent leukopenia without and grade 4 thrombocytopenia with support of lenograstim.",
keywords = "Carboplatin, Cisplatin, Ovarian neoplasms, Platinum dose-intensity",
author = "Sandro Pignata and Rossella Lauria and Francesco Perrone and Ettore Ferrari and Edoardo Biondi and Antonio Maffeo and Alessandro Morabito and Raffaele Graziano and Chiara Carlomagno and {De Placido}, Giuseppe and Giro Gallo and Bianco, {Angelo Raffaele} and Mario Pergola and {De Placido}, Sabino",
year = "1997",
language = "English",
volume = "11",
pages = "175--180",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer

AU - Pignata, Sandro

AU - Lauria, Rossella

AU - Perrone, Francesco

AU - Ferrari, Ettore

AU - Biondi, Edoardo

AU - Maffeo, Antonio

AU - Morabito, Alessandro

AU - Graziano, Raffaele

AU - Carlomagno, Chiara

AU - De Placido, Giuseppe

AU - Gallo, Giro

AU - Bianco, Angelo Raffaele

AU - Pergola, Mario

AU - De Placido, Sabino

PY - 1997

Y1 - 1997

N2 - Cisplatin and carboplatin are both active in ovarian cancer with different toxicity profiles; thus, dose intensification may be possible by combining them. The aim of the present study was to determine the maximum tolerated dose of carboplatin combined with fixed doses of cisplatin and cyclophosphamide without and with support of lenograstim. Cisplatin (60 mg/m2), cyclophosphamide (600 mg/m2) and carboplatin (starting dose 200 mg/m2) were given on day 1 every 3 weeks for 4 cycles. Escalated dose levels for carboplatin were planned by increments of 50 mg/m2 per level. Lenograstim (L) (150 μg/m2/day subcutaneously) was given in case of grade 4 leukopenia (levels without support) or from day 5 up to leukocyte >10,000/mm3 after nadir (levels with support). Four levels were studied (200, 250, 250 + lenograstim, 300 + lenograstim) with 7, 7, 8, and 7 patients enrolled, respectively. Unacceptable toxicity was induced in 1 patient at the level 1 (grade 4 thrombocytopenia), in 4 patients at the level 2 (2 prolonged grade 2 leukopenia, 1 grade 4 leukopenia with concomitant grade 4 thrombocytopenia and I grade 4 thrombocytopenia), in 1 patient at the level 2 + L (grade 4 thrombocytopenia) and in 3 patients at the level 3 + L (3 grade 4 thrombocytopenia). Thus, 200 mg/m2 and 250 mg/m2 were defined as carboplatin MTDs without and with lenograstim support, respectively. Median total platinum (cisplatin + 1/4 carboplatin) delivered dose-intensities were 33, 32, 38 and 44 mg/m2/week at the four levels, respectively. Hematological toxicity was overall mild. In no case was febrile neutropenia recorded. Grade 4 thrombocytopenia was always transient and never symptomatic. Grade 3 vomiting was the only severe non-hematological toxicity reported in 5 patients. Out of 16 patients with measurable disease, 11 objective responses were obtained (5 complete and 6 partial) for an overall response rate of 69% (95% exact CL 41-89%). Recommended dose of carboplatin is 200 mg/m2 without and 250 mg/m2 with support of lenograstim when combined with cisplatin 60 mg/m2 and cyclophosphamide 600 mg/m2. Dose limiting toxicity is persistent leukopenia without and grade 4 thrombocytopenia with support of lenograstim.

AB - Cisplatin and carboplatin are both active in ovarian cancer with different toxicity profiles; thus, dose intensification may be possible by combining them. The aim of the present study was to determine the maximum tolerated dose of carboplatin combined with fixed doses of cisplatin and cyclophosphamide without and with support of lenograstim. Cisplatin (60 mg/m2), cyclophosphamide (600 mg/m2) and carboplatin (starting dose 200 mg/m2) were given on day 1 every 3 weeks for 4 cycles. Escalated dose levels for carboplatin were planned by increments of 50 mg/m2 per level. Lenograstim (L) (150 μg/m2/day subcutaneously) was given in case of grade 4 leukopenia (levels without support) or from day 5 up to leukocyte >10,000/mm3 after nadir (levels with support). Four levels were studied (200, 250, 250 + lenograstim, 300 + lenograstim) with 7, 7, 8, and 7 patients enrolled, respectively. Unacceptable toxicity was induced in 1 patient at the level 1 (grade 4 thrombocytopenia), in 4 patients at the level 2 (2 prolonged grade 2 leukopenia, 1 grade 4 leukopenia with concomitant grade 4 thrombocytopenia and I grade 4 thrombocytopenia), in 1 patient at the level 2 + L (grade 4 thrombocytopenia) and in 3 patients at the level 3 + L (3 grade 4 thrombocytopenia). Thus, 200 mg/m2 and 250 mg/m2 were defined as carboplatin MTDs without and with lenograstim support, respectively. Median total platinum (cisplatin + 1/4 carboplatin) delivered dose-intensities were 33, 32, 38 and 44 mg/m2/week at the four levels, respectively. Hematological toxicity was overall mild. In no case was febrile neutropenia recorded. Grade 4 thrombocytopenia was always transient and never symptomatic. Grade 3 vomiting was the only severe non-hematological toxicity reported in 5 patients. Out of 16 patients with measurable disease, 11 objective responses were obtained (5 complete and 6 partial) for an overall response rate of 69% (95% exact CL 41-89%). Recommended dose of carboplatin is 200 mg/m2 without and 250 mg/m2 with support of lenograstim when combined with cisplatin 60 mg/m2 and cyclophosphamide 600 mg/m2. Dose limiting toxicity is persistent leukopenia without and grade 4 thrombocytopenia with support of lenograstim.

KW - Carboplatin

KW - Cisplatin

KW - Ovarian neoplasms

KW - Platinum dose-intensity

UR - http://www.scopus.com/inward/record.url?scp=12644263414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12644263414&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 175

EP - 180

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -